The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

Bladder Cancer Clinical Trial

Official title:

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03591367
• Other study ID #: MicroRNA-155 Bladder Cancer
• Status: Completed
• Phase: N/A
• Start date: August 1, 2018
• Est. completion date: May 1, 2019

Study information

• Verified date: July 2018
• Source: Mansoura University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We try to assess the potential role of telomerase reverse transcriptase and MicroRNA (miR-155) in diagnosis of non-muscle-invasive bladder cancer and their correlation with stage and grade of the tumor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 115
• Est. completion date: May 1, 2019
• Est. primary completion date: May 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women 18 years or older.

• Patient with hematuria suspected to be of bladder origin clinically.

• Willing to be participate in the study.

Exclusion Criteria:

• Patient having another malignancy.

• Hematuria of other causes as trauma and stones

Related Conditions & MeSH terms

• Bladder Cancer
• Bladder Disease
• Bladder Neoplasm
• Micro-RNA
• Urinary Bladder Diseases
• Urinary Bladder Neoplasms

Intervention

Diagnostic Test:
• MicroRNAs-155
Quantitative analysis of cell-free miR-155 using RT-qPCR.
• Human telomerase reverse transcriptase
Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.

Locations

Country	Name	City	State
Egypt	Urology and Nephrology Center	Mansourah	Aldakahlia

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	sensitivity, specificity and positive and negative predictive values of combined MicroRNA-155 And Telomerase Reverse Transcriptase In diagnosis Of Non-Muscle Invasive Bladder Cancer	compared by standard final pathological specimen	1 year
Secondary	correlation between serum Vit D and Non-Muscle Invasive Bladder Cancer	measured serum Vit D in ng/mL.	1 year